Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The challenge of diagnosing constitutional mismatch repair deficiency syndrome in brain malignancies from young individuals

  • Carrato, Cristina|||0000-0002-1953-8287
  • Sanz, Carolina|||0009-0001-9228-755X
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Pineda, Marta|||0000-0002-5403-5845
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Dámaso, Estela|||0000-0002-9650-7791
  • Esteller, M|||0000-0003-4490-6093
  • Musulén, Eva|||0000-0002-9667-6464
Biallelic germline mismatch repair (MMR) gene (MLH1, MSH2, MSH6, and PMS2) mutations are an extremely rare event that causes constitutional mismatch repair deficiency (CMMRD) syndrome. CMMRD is underdiagnosed and often debuts with pediatric malignant brain tumors. A high degree of clinical awareness of the CMMRD phenotype is needed to identify new cases. Immunohistochemical (IHC) assessment of MMR protein expression and analysis of microsatellite instability (MSI) are the first tools with which to initiate the study of this syndrome in solid malignancies. MMR IHC shows a hallmark pattern with absence of staining in both neoplastic and non-neoplastic cells for the biallelic mutated gene. However, MSI often fails in brain malignancies. The aim of this report is to draw attention to the peculiar IHC profile that characterizes CMMRD syndrome and to review the difficulties in reaching an accurate diagnosis by describing the case of two siblings with biallelic MSH6 germline mutations and brain tumors. Given the difficulties involved in early diagnosis of CMMRD we propose the use of the IHC of MMR proteins in all malignant brain tumors diagnosed in individuals younger than 25 years-old to facilitate the diagnosis of CMMRD and to select those neoplasms that will benefit from immunotherapy treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary

  • Blecua, Pedro|||0000-0002-1012-0300
  • Davalos, Veronica|||0000-0003-4077-5137
  • De Villasante, Izar|||0000-0001-7325-0631
  • Merkel, Angelika|||0000-0001-5164-6803
  • Musulén, Eva|||0000-0002-9667-6464
  • Coll-Sanmartin, Laia
  • Esteller, M|||0000-0003-4490-6093
High-throughput genomic technologies are increasingly used in personalized cancer medicine. However, computational tools to maximize the use of scarce tissues combining distinct molecular layers are needed. Here we present a refined strategy, based on the R-package 'conumee', to better predict somatic copy number alterations (SCNA) from deoxyribonucleic acid (DNA) methylation arrays. Our approach, termed hereafter as 'conumee-KCN', improves SCNA prediction by incorporating tumor purity and dynamic thresholding. We trained our algorithm using paired DNA methylation and SNP Array 6.0 data from The Cancer Genome Atlas samples and confirmed its performance in cancer cell lines. Most importantly, the application of our approach in cancers of unknown primary identified amplified potentially actionable targets that were experimentally validated by Fluorescence in situ hybridization and immunostaining, reaching 100% specificity and 93.3% sensitivity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Towards a druggable epitranscriptome, Compounds that target RNA modifications in cancer

  • Berdasco, Maria|||0000-0002-6750-0400
  • Esteller, M|||0000-0003-4490-6093
Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field has been opened up by the technical efforts of the last decade to characterize and quantify RNA modifications, and this has led to a map of post-transcriptional RNA marks in normal cell fate and development. However, the scientific interest has been fuelled by the discovery of aberrant epitranscriptomes associated with human diseases, mainly cancer. The challenge is now to see whether epitrancriptomics offers mechanisms that can be effectively targeted by low MW compounds and are thus druggable. In this review, we will describe the principal RNA modifications (with a focus on mRNA), summarize the latest scientific evidence of their dysregulation in cancer and provide an overview of the state-of-the-art drug discovery to target the epitranscriptome. Finally, we will discuss the principal challenges in the field of chemical biology and drug development to increase the potential of targeted-RNA for clinical benefit. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 285,000 CpG sites in the mouse genome

  • García-Prieto, Carlos A|||0000-0001-5021-6916
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Musulén, Eva|||0000-0002-9667-6464
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Vazquez Prat, Berta Nieves|||0000-0002-8164-3926
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Esteller, M|||0000-0003-4490-6093
Mouse has been extensively used as a model organism in many studies to characterize biological pathways and drug effects and to mimic human diseases. Similar DNA sequences between both species facilitate these types of experiments. However, much less is known about the mouse epigenome, particularly for DNA methylation. Progress in delivering mouse DNA methylomes has been slow due to the currently available time-consuming and expensive methodologies. Following the great acceptance of the human DNA methylation microarrays, we have herein validated a newly developed DNA methylation microarray (Infinium Mouse Methylation BeadChip) that interrogates 280,754 unique CpG sites within the mouse genome. The CpGs included in the platform cover CpG Islands, shores, shelves and open sea sequences, and loci surrounding transcription start sites and gene bodies. From a functional standpoint, mouse ENCODE representative DNase hypersensitivity sites (rDHSs) and candidate cis-Regulatory Elements (cCREs) are also included. Herein, we show that the profiled mouse DNA methylation microarray provides reliable values among technical replicates; matched results from fresh frozen versus formalin-fixed samples; detects hemimethylated X-chromosome and imprinted CpG sites; and is able to determine CpG methylation changes in mouse cell lines treated with a DNA demethylating agent or upon genetic disruption of a DNA methyltransferase. Most important, using unsupervised hierarchical clustering and t-SNE approaches, the platform is able to classify all types of normal mouse tissues and organs. These data underscore the great features of the assessed microarray to obtain comprehensive DNA methylation profiles of the mouse genome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies

  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Davalos, Veronica|||0000-0003-4077-5137
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Delgado, Julia
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Del Bufalo, Francesca
  • Locatelli, Franco|||0000-0002-7976-3654
  • Quintarelli, Concetta
  • Sinibaldi, Matilde
  • Soler, Marta|||0000-0002-6656-957X
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • Fernandez, Agustin F.
  • Fraga, Mario|||0000-0001-8450-2603
  • Bar, Diana
  • Meir, Agustín
  • Itzhaki, Orit
  • Besser, MichalJ.
  • Avigdor, Abraham
  • Jacoby, Elad
  • Esteller, M.|||0000-0003-4490-6093
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. The increasingly recognized relevance of epigenetic changes in cancer immunology prompted us to determine the impact of the DNA methylation profiles of CART19 cells on the clinical course. Methods: We recruited 114 patients with B-cell malignancies, comprising 77 patients with acute lymphoblastic leukemia and 37 patients with non-Hodgkin lymphoma who were treated with CART19 cells. Using a comprehensive DNA methylation microarray, we determined the epigenomic changes that occur in the patient T cells upon transduction of the CAR vector. The effects of the identified DNA methylation sites on clinical response, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, event-free survival, and overall survival were assessed. All statistical tests were 2-sided. Results: We identified 984 genomic sites with differential DNA methylation between CAR-untransduced and CAR-transduced T cells before infusion into the patient. Eighteen of these distinct epigenetic loci were associated with complete response (CR), adjusting by multiple testing. Using the sites linked to CR, an epigenetic signature, referred to hereafter as the EPICART signature, was established in the initial discovery cohort (n = 79), which was associated with CR (Fisher exact test, P <. 001) and enhanced event-free survival (hazard ratio [HR] = 0.36; 95% confidence interval [CI] = 0.19 to 0.70; P =. 002; log-rank P =. 003) and overall survival (HR = 0.45; 95% CI = 0.20 to 0.99; P =. 047; log-rank P =. 04;). Most important, the EPICART profile maintained its clinical course predictive value in the validation cohort (n = 35), where it was associated with CR (Fisher exact test, P <. 001) and enhanced overall survival (HR = 0.31; 95% CI = 0.11 to 0.84; P =. 02; log-rank P =. 02). Conclusions: We show that the DNA methylation landscape of patient CART19 cells influences the efficacy of the cellular immunotherapy treatment in patients with B-cell malignancy.